EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
-11.3%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$957M
AUM Growth
+$957M
(-9.2%)
Cap. Flow
+$74.6M
Cap. Flow
% of AUM
7.79%
Top 10 Holdings %
Top 10 Hldgs %
58.48%
Holding
64
New
21
Increased
9
Reduced
14
Closed
12
Top Buys
| 1 |
Fate Therapeutics
FATE
|
$42M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$22.5M |
| 3 |
Puma Biotechnology
PBYI
|
$21.4M |
| 4 |
AnaptysBio
ANAB
|
$15.1M |
| 5 |
Sangamo Therapeutics
SGMO
|
$14.7M |
Top Sells
| 1 |
argenx
ARGX
|
$32.4M |
| 2 |
FibroGen
FGEN
|
$21.2M |
| 3 |
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
|
$13.4M |
| 4 |
SAGE
Sage Therapeutics
SAGE
|
$12.5M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$7.44M |
Sector Composition
| 1 | Healthcare | 92.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ionis Pharmaceuticals
IONS
$6.8B
| $9.86M | 1.03% | +208,609 | New | +$9.86M |
|
27
Vir Biotechnology
VIR
$686M
| $9.27M | 0.97% | +270,418 | New | +$9.27M |
|
28
Alaunos Therapeutics
TCRT
$4.21M
| $9.19M | 0.96% | +3,750,000 | New | +$9.19M |
|
29
Verastem
VSTM
$569M
| $8.6M | 0.9% | +3,255,813 | New | +$8.6M |
|
|
BMY.RT
30
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $8.54M | 0.89% | +2,248,300 | New | +$8.54M |
|
31
Cyclerion Therapeutics
CYCN
$7.91M
| $7.27M | 0.76% | 2,742,276 +931,276 | +51% | +$2.47M |
|
|
CHMA
32
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $5.52M | 0.58% | 1,512,627 -1,531,200 | -50% | -$5.59M |
|
33
Crinetics Pharmaceuticals
CRNX
$2.92B
| $5.15M | 0.54% | +350,000 | New | +$5.15M |
|
34
Exicure
XCUR
$35.4M
| $4.21M | 0.44% | 2,841,301 -702,885 | -20% | -$1.04M |
|
35
Arcus Biosciences
RCUS
$1.13B
| $4.05M | 0.42% | 292,100 -437,805 | -60% | -$6.08M |
|
36
Savara
SVRA
$567M
| $3.04M | 0.32% | 1,432,664 | – | – |
|
|
LSACU
37
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
| $3M | 0.31% | +300,000 | New | +$3M |
|
|
SURF
38
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $2.38M | 0.25% | 1,274,463 -27,250 | -2% | -$51K |
|
39
Aclaris Therapeutics
ACRS
$209M
| $2.17M | 0.23% | 2,087,312 | – | – |
|
40
Corvus Pharmaceuticals
CRVS
$428M
| $1.56M | 0.16% | 737,612 | – | – |
|
41
Zymeworks
ZYME
$1.12B
| $1.47M | 0.15% | +41,407 | New | +$1.47M |
|
42
CRISPR Therapeutics
CRSP
$4.71B
| $1.29M | 0.14% | +30,510 | New | +$1.29M |
|
43
MeiraGTx Holdings
MGTX
$587M
| $1.27M | 0.13% | +94,819 | New | +$1.27M |
|
|
TRIL
44
DELISTED
Trillium Therapeutics Inc.
TRIL
| $1.18M | 0.12% | +291,997 | New | +$1.18M |
|
45
Xoma
XOMA
$392M
| $1.03M | 0.11% | +50,809 | New | +$1.03M |
|
|
RGLS
46
DELISTED
Regulus Therapeutics
RGLS
| $870K | 0.09% | +1,886,812 | New | +$870K |
|
|
BPMC
47
DELISTED
Blueprint Medicines
BPMC
| $816K | 0.09% | +13,946 | New | +$816K |
|
|
PVLA
48
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $602K | 0.06% | 264,166 -2,271,046 | -90% | -$5.18M |
|
|
FPRX
49
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $581K | 0.06% | +256,075 | New | +$581K |
|
50
Exelixis
EXEL
$10.1B
| $108K | 0.01% | +6,269 | New | +$108K |
|